New research presented at the Obesity Week 2024 meeting suggests that the oral semaglutide 25 mg dose is just as effective in promoting weight loss and other positive outcomes as the investigational 50-mg oral dose and the injectable 2.4-mg dose. The OASIS 4 trial showed that the 25-mg dose may be an effective option for treating overweight and obesity, especially for patients who prefer oral administration. The trial demonstrated significant reductions in body weight, blood pressure, A1c, fasting plasma glucose, and lipid levels with oral semaglutide. Adverse events, particularly gastrointestinal, were more common with oral semaglutide but were manageable.
Source link
Oral Semaglutide 25-mg Dose May Provide Most Benefit
